Hospira

Activities: Drug Delivery Pharmaceutical

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Regulatory

FDA cautions Pfizer subsidiary in India in quality control warning letter

The letter is the result of an inspection at Hospira Healthcare India that identified GMP violations in quality control, data integrity, and microbial control
Drug Delivery

Mylan and Hospira voluntarily recall injectables

Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet
Regulatory

Brussels explains why it approved Pfizer/Hospira deal

Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory

Hospira calls for biosimilars to have same name as biologicals

Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Research & Development

Hospira and Pfenex link up to develop Lucentis biosimilar

Pfenex will receive US$51m upfront once the collaboration receives antitrust approval
Drug Delivery

Pfizer to acquire Hospira

Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira
Manufacturing

Opinion: Still not getting it right

The future for pharma development is bright, but there are still too many potentially dangerous recalls in the manufacturing sector
Subscribe now